The hepatocellular carcinoma drugs global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Hepatocellular Carcinoma Drugs Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The hepatocellular carcinoma drugs market size has grown strongly in recent years. It will grow from $1.07 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increased disease incidence, advancements in cancer research, global healthcare infrastructure improvement, regulatory approvals, awareness and early diagnosis initiatives..
The hepatocellular carcinoma drugs market size is expected to see strong growth in the next few years. It will grow to $1.62 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to targeted therapies advancements, increasing geriatric population, healthcare personalization trends, global expansion of treatment access.. Major trends in the forecast period include access to innovative therapies, patient-centric care, regulatory advancements, drug resistance mitigation strategies, collaborative research initiatives..
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/hepatocellular-carcinoma-drugs-global-market-report
Scope Of Hepatocellular Carcinoma Drugs Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Hepatocellular Carcinoma Drugs Market Overview
Market Drivers –
The rise in the occurrence of hepatocellular carcinoma is expected to propel the growth of the hepatocellular carcinoma drug market over the coming years. Hepatocellular carcinoma (HCC) is a primary malignant disease of the liver and the most common form of liver cancer. Hepatocellular carcinoma starts with the main type of liver cells called hepatocyte cells. Most cases of HCC result from infection with hepatitis B or C, or cirrhosis. As the occurrence of hepatocellular carcinoma continuing to rise, it leads to an increased demand for effective hepatocellular carcinoma drugs to treat the disease. For instance, in 2023, according to the report published by the American Cancer Society, Inc, a US-based nationwide voluntary health organization dedicated to eliminating cancer, estimated new cases of liver cancer in females diagnosed in the United States increased from 12,660 in 2022 to 13,230 in 2023. Therefore, the rise in the occurrence of hepatocellular carcinoma is driving the growth of the hepatocellular carcinoma drug market.
Market Trends –
Major companies operating in the hepatocellular carcinoma drugs market are developing laboratory-produced molecule such as monoclonal antibodies (mAb) to meet larger customer bases, more sales, and increase revenue. A monoclonal antibody (mAb) is a laboratory-produced molecule that is engineered to mimic the immune system’s ability to fight off harmful pathogens such as bacteria or viruses. For instance, in October 2022, AstraZeneca Plc, a UK-based pharmaceutical and biotechnology company, announced the US Food and Drug Administration (FDA) approval for Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) Indicated for adult patients with hepatocellular carcinoma (HCC). Imfinzi (durvalumab) is a distinctive human monoclonal antibody that effectively binds to the PD-L1 protein. By doing so, it hinders the interaction between PD-L1 and the PD-1 and CD80 proteins. This action disrupts the tumor’s evasion of the immune system, releasing the inhibition of immune responses. As for Imjudo (tremelimumab), it stands out as a human monoclonal antibody designed to specifically target the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imjudo works by blocking CTLA-4 activity, thereby promoting T-cell activation, priming the immune response against cancer, and fostering the death of cancer cells.
The hepatocellular carcinoma drugs market covered in this report is segmented –
1) By Type: Brachytherapy, Chemotherapy
2) By Drug Class: PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors
3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers
Get an inside scoop of the hepatocellular carcinoma drugs market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=10809&type=smp
Regional Insights –
North America was the largest region in the hepatocellular carcinoma drug market in 2023. The regions covered in the hepatocellular carcinoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Key Companies –
Major companies operating in the hepatocellular carcinoma drugs market report are AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Co.Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., GlaxoSmithKline, Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG, Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., TTY Biopharm Company Limited, Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, Jiangsu Hengrui Medicine Co. Ltd.
Table of Contents
1. Executive Summary
2. Hepatocellular Carcinoma Drugs Market Report Structure
3. Hepatocellular Carcinoma Drugs Market Trends And Strategies
4. Hepatocellular Carcinoma Drugs Market – Macro Economic Scenario
5. Hepatocellular Carcinoma Drugs Market Size And Growth
…..
27. Hepatocellular Carcinoma Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
